Local media: UC, UC Health to examine potential COVID-19 treatment
In the absence of an approved treatment for COVID-19, in March the FDA began allowing researchers to request emergency authorization for the use of convalescent plasma which shows potential as a treatment for the disease.
Researchers at the UC College of Medicine are among those who joined the Mayo Clinic protocol for investigating convalescent plasma as a possible treatment for COVID-19. Convalescent plasma is obtained from people who have recovered from COVID-19 and have been free of symptoms for 28 days. This program may allow access to that plasma for hospitalized patients infected with the novel coronavirus who have severe or life-threatening COVID-19, or who may be at high risk for progression to severe or life-threatening disease.
This research garnered coverage from the Cincinnati Business Courier, Cincinnati Enquirer, WLWT, Fox19 and WVXU.
Featured image at top from freestocks on Unsplash.
Find the latest details related to coronavirus disease 2019 (covid-19) on the Centers for Disease Control and Prevention (CDC) website, and follow UC's latest information with regard to the virus.
Related Stories
Recent advances may speed time to endometriosis diagnosis
March 16, 2026
The average time to clinical diagnosis of endometriosis is nine years. Definitive diagnosis of the disease is difficult, and until recently, has relied on laparoscopic surgery. Now, as Medscape recently reported, novel clinical recommendations, advanced diagnostic tools and research into inflammation and immune responses, are bringing promise that women with endometriosis will find relief sooner and without surgery, according to experts, including Katie Burns, PhD, University of Cincinnati College of Medicine associate professor.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.